Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls

• Keefe Bruyette upgraded Toll Brothers (TOL) to Outperform from Market Perform with a terms people of $161, up from $158. The steadfast says the upgrade reflects Toll's vulnerability to "resilient" luxury demand, its long-land ostentation hedge, and improved fundamentals station the fiscal Q2 report.

• UBS upgraded Arthur J. Gallagher (AJG) to Buy from Neutral with a terms people of $250, down from $283. The firm's presumption is supra statement connected margins by 70 ground points done 2026-2028 arsenic UBS sees upside from AssuredPartners synergies and AI-driven outgo savings being underestimated.

• Citi upgraded PTC Therapeutics (PTCT) to Buy from Neutral with a terms people of $108, up from $75, aft a transportation successful expert coverage. The steadfast cites its bullish outlook for Sephience successful phenylketonuria for the upgrade.

• JPMorgan upgraded Par Technology (PAR) to Neutral from Underweight with a terms people of $16, up from $12. The steadfast says that owed to a method error, its initiation study connected May 29 overstated the stock number of Par.

• Canaccord upgraded FuelCell (FCEL) to Buy from Hold with a terms people of $30, up from $12. The steadfast cites the company's imaginable accidental implicit the coming years successful the information halfway marketplace for the upgrade.

Top 5 Downgrades:

• Keefe Bruyette downgraded Lennar (LEN) to Underperform from Market Perform with a terms people of $86, down from $97. The steadfast says the downgrade of Lennar reflects the company's precocious entry-level vulnerability successful a challenging request and complaint backdrop and ongoing borderline headwinds from the Millrose onshore enactment structure.

• Argus downgraded Prudential (PRU) to Hold from Buy. The steadfast notes the company's ongoing Japan issues, citing its April announcement that it would widen the suspension of caller income successful Japan by an further 180 days portion extending the anterior announcement of a 90-day suspension successful February.

• Oppenheimer downgraded Ingredion (INGR) to Perform from Outperform and removed the firm's anterior terms people pursuing the company's projected Tate & Lyle acquisition.

• RBC Capital downgraded Equity Residential (EQR) to Sector Perform from Outperform with a terms people of $70, up from $69. The steadfast expects a play of little visibility into the adjacent of the AvalonBay (AVB) merger.

• Piper Sandler downgraded Nuvalent (NUVL) to Neutral from Overweight with a $124 terms people aft GSK (GSK) agreed to get the institution for $10.6B, oregon $124 per stock successful cash. LifeSci Capital, Wells Fargo, Raymond James and Wedbush besides downgraded Nuvalent to Neutral-equivalent ratings.